By Fineline Cube CSPC Pharmaceutical Group (HKG: 1093) announced that China’s National Medical Products Administration (NMPA) has accepted for review its marketing application for a biosimilar of Novartis’ Cosentyx (secukinumab), a fully human IgG1 monoclonal antibody targeting interleukin-17A (IL-17A) for immune-inflammatory diseases including psoriasis and ankylosing spondylitis.
Regulatory Milestone
| Parameter | Detail |
|---|---|
| Regulatory Agency | NMPA (China) |
| Application Status | Accepted for review |
| Reference Product | Cosentyx (secukinumab) – Novartis |
| Target Indications | Psoriasis, ankylosing spondylitis, and other IL-17A-mediated conditions |
| Molecule Type | Fully human IgG1 monoclonal antibody |
| Target | Interleukin-17A (IL-17A) |
Clinical Development & Analytical Evidence
- Phase III Equivalence Study: Demonstrated high similarity to reference Cosentyx across all critical quality attributes
- Efficacy Profile: Equivalent therapeutic outcomes in primary and secondary endpoints
- Safety Characteristics: Comparable adverse event rates and safety profile
- Pharmacokinetics (PK): Bioequivalent exposure parameters (AUC, Cmax, half-life)
- Immunogenicity: Similar anti-drug antibody formation rates and neutralizing antibody profiles
The comprehensive analytical and clinical package supports the biosimilarity claim required under China’s stringent biosimilar regulatory framework, which aligns with international standards established by EMA and FDA.
Market Dynamics & Commercial Outlook
- Cosentyx Market Leadership: Original product generated CHF 4.7 billion globally in 2025, with China representing one of the fastest-growing markets due to high prevalence of psoriasis and limited biologic access historically
- Chinese Psoriasis Burden: Estimated 6.7 million patients with moderate-to-severe psoriasis, with biologic penetration rate below 15% compared to 40%+ in developed markets
- Competitive Landscape: CSPC enters a crowded but expanding Chinese IL-17A biosimilar market, competing with products from Qilu Pharmaceutical, Innovent Biologics, and Alphamab Oncology
- Pricing Strategy: Expected to offer 30-40% discount versus originator, potentially accelerating biologic adoption among Chinese patients
Strategic Significance for CSPC
This filing represents CSPC’s continued expansion into the high-value monoclonal antibody biosimilars segment, complementing its recently announced SYHX2008 octreotide biosimilar program. The company’s investment in advanced analytical characterization capabilities and clinical development infrastructure positions it as a leading Chinese biosimilars developer targeting both domestic and international markets.
Industry analysts project the Chinese secukinumab biosimilar market could reach RMB 5-7 billion annually by 2028, with first-mover advantage providing significant commercial benefits despite increasing competition.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and competitive positioning. Actual results may differ due to regulatory decisions, market dynamics, and competitor actions.-Fineline Info & Tech